leadf
logo-loader
viewPolarean Imaging PLC

Polarean Imaging updates on clinical trials ahead of investor symposium

Polarean Imaging PLC's (LON:POLX) chief executive Richard Hullihen tells Proactive London's Andrew Scott the enrolment of the final few patients for clinical testing of its drug-device combination for MRI lung scans will soon begin at a third trial site.

They've so far enrolled 85.4% of the required number of patients in the lung transplant pathway and 62.5% for the lung resection pathway.

This is up from 80% and 50% in mid-May.

Quick facts: Polarean Imaging PLC

Price: 40.5 GBX

AIM:POLX
Market: AIM
Market Cap: £65.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

on 19/6/20

2 min read